Stock Events

Stock Events

Viridian Therapeutics

$13.5

13

+$0.05+0.37% Today

Statistics

Day High

13.89

Day Low

-

52W High

28.35

52W Low

10.93

Volume

726,604

Avg. Volume

847,089

Mkt Cap

861.6M

P/E Ratio

-3.06

Dividend Yield

-

Dividend

-

Earnings

8MayConfirmed

Q3 2022

Q4 2022

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

-1.61

-1.32

-1.02

-0.73

Expected EPS

-1.1

Actual EPS

-0.79

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRDN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on treatments for eye diseases, allergic and inflammatory diseases, which overlaps with Viridian's therapeutic areas.

Gilead Sciences

Gilead Sciences is involved in the discovery, development, and commercialization of therapeutics in areas such as viral diseases, inflammatory and fibrotic diseases, which can compete with Viridian's product pipeline.

Vertex Pharmaceuticals

Vertex Pharmaceuticals focuses on creating new possibilities in medicine to cure diseases and improve people's lives, including treatments for cystic fibrosis, competing in the biotech space with Viridian.

Amgen is a biotechnology pioneer that discovers, develops, manufactures, and delivers innovative human therapeutics, including treatments for inflammatory diseases, which competes with Viridian's focus areas.

Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, competing with Viridian in the biopharmaceutical sector.

AbbVie's business is focused on delivering transformative therapies in areas such as immunology and oncology, which can compete with Viridian's therapeutic development programs.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care, but also has a growing presence in biopharmaceuticals that could compete with Viridian.

AstraZeneca has a broad portfolio in various therapeutic areas, including respiratory, cardiovascular, and oncology, potentially competing with Viridian's focus on innovative therapeutics.

Pfizer is a global biopharmaceutical company that develops and manufactures healthcare products including medicines and vaccines for a wide range of conditions, competing with Viridian in the healthcare sector.

Merck operates globally and offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing with Viridian in the pharmaceutical and healthcare market.

Analyst Ratings

30.5$Average Price Target

The highest estimate is $40.

From 7 ratings within the last 6 months. This is not an investment recommendation.

Buy

71%

Hold

29%

Sell

0%

About

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Show more...

CEO

William Marshall

Employees

94

Country

US

ISIN

US92790C1045

WKN

000A2QMUH

Listings